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Abstract 
 
Access to diastereoisomeric forms of original spirolactam frameworks and investigation of their folded 25 
potentials are depicted here. Taking advantage of a stereoselective ring-contraction reaction, the 
Transannular Rearrangement of Activated Lactams (TRAL), followed by two unprecedented tandem 
reactions, we described here an efficient access to elegant spirocyclic scaffolds. After dimerization, 
NMR analyses, Circular Dichroism, SEM and Molecular Modelling highlighted an attractive edifice 
able to fold and behave as a PPII helix, a common yet neglected peptidic secondary structure. 30 
 
Introduction 
 
Spirocycle moieties are encountered in many natural products1–6 which made this particular bicycle a 
key platform for medicinal chemists.7–10 Due to their highly constrained structures,11–13 35 
spirocompounds were also described for their interesting properties as folded materials14–16 and for 
their efficiency as catalysts17 or molecular actuators.18 However, very few articles have reported their 
use as peptidomimetics or tools to explore protein-protein interactions19–23 which are largely mediated 
by the recognition of proline-rich modules generally described to be structured in polyproline II helices 
(PPII). They represent attractive targets for the medicinal chemist,24–28 being the architectural hallmark 40 
of linear sequences recognizing protein-protein interaction modules such as SH3, WW and EVH1 
domains.24–26,29 Formerly neglected, the significance of this unique extended structure and its 
implication in crucial pathologies29,30 have recently stimulated few chemists to synthesize PPII 
mimics.31 They essentially concern the synthesis of polyimide-based foldamers,32–34 PTAAs,35–37 
triproline mimics,38,39 Ser-Pro dipeptide40 or Pro-Pro dipeptide mimics.41 However, compared to the 
ever-growing field of α-helices or β-turn mimics, only few approaches have been described to emulate 
the PPII structure. Then, the discovery of pertinent PPII scaffolds to target protein-protein molecular 5 
interactions is still completely relevant to understand their biological significance.
 
In this context, we wished here to present the access to dimeric spirolactam structures, one of which 
was capable of behaving as polyproline II helix. We reported our first steps in the development of a 
new class of artificial bio-inspired PPII compounds, part of a challenging research on pertinent tools 10 
for the understanding of protein-protein interaction.  
 
In order to build spirolactam platforms, the Transannular Rearrangement of Activated Lactams 
(TRAL) has proven to be a central and optimal tool. More particularly, we described in this article a 
careful study on the stereochemical potential of this rearrangement for the design of unprecedented 15 
heterocyclic frameworks. Starting from N,N’-bis-Boc-activated diketopiperazines (DKP), the six- to 
five-membered ring-contraction yielded aminotetramate scaffolds with high stereoselectivity.42 The 
broad interest of the reaction was previously demonstrated by the preparation of diverse scaffolds such 
as statins or pentacins analogues.43–45 While a protonation in aqueous medium yielded TRAL product, 
addition in the reaction mixture of an alkylating agent allowed the formation and isolation of the 20 
TRAL-alkylation product (Scheme 1). 
 
In the present work, we deliberately chose the commercially available Shöllkopf’s DKP, given the 
exceptional stereoselectivity of the TRAL, as a model to further access spirolactam moieties. We 
herein reported a preliminary pathway to such constrained structures in a first part, using the TRAL-25 
alkylation tandem reaction, the quickest way to prepare substituted pyrrolidine-2,4-diones. In the 
second part of our study, we then disclosed an alternative access to spirolactam constructs, 
highlighting an attractive edifice able to fold and behave as a PPII helix.
 
Results and Discussion 30 
 
First route to spirolactam scaffolds 
 
The TRAL-alkylation found hence its interest in the construction of substituted pyrrolidine-2,4-diones 
with a high to total diastereoselectivity, depending on the steric hindrance of the starting DKP’s side-35 
chain. After a preliminary protection/activation step of the lactams using Boc2O and DMAP, the 
resulting activated N,N’-bis-Boc-cyclo-[Gly-(D)-Val] model was submitted to the TRAL-alkylation 
conditions using ethyl 2-(bromomethyl)acrylate as the alkylating agent (Scheme 2). The reaction 
proceeded with a total diastereoselectivity furnishing the R,R-diastereoisomer 2 with a yield of 38%. 
As we recently reported,44 it is always difficult to propose a predictable and rational chemical 40 
reactivity for the TRAL-alkylation, the major by-product here resulting from a direct alkylation of the 
starting DKP.  
 
After a facile deprotection of the Boc-moieties allowing isolation of the trifluoroacetate salt of the 
primary amine, we chose to increase functional diversity on our scaffold. Taking advantage of the 45 
acrylate moiety, a benzylamino group was located in the following step via a suitable Michael 
addition. At this stage we observed the 1,4-addition of benzylamine, concomitant with the 
spirocyclisation, without any detectable trace of 1,2-addition. Excess of benzylamine under microwave 
irradiation triggered a one-pot spirocyclisation concomitant with an aza-Michael addition. This tandem 
reaction led to 95% of conversion of the starting material into the functionalized original spirolactam 
3. Concurrently, the presence of a keto group caused the formation of a Schiff base which needed to be 
further hydrolysed with aqueous 1 N HCl. This unprecedented reaction which is in fact a combination 5 
of three different synthetic steps – a 1,4-addition of benzylamine on the ethyl acrylate moiety, and an 
intramolecular cyclization concomitant with a Schiff base formation – opened thus access to 
innovative spirolactam scaffolds with excellent yield. 
 
Only one epimer was isolated (3a, for details, please refer to Electronic Supporting Information), 10 
which then underwent a stereocontrolled reduction using sodium borohydride to provide a crystalline 
spirolactam 4.  
 
NOESY experiments performed on compound 4, revealing strong correlations between hydrogen 7, 16 
and 17, allowed us to confirm the 9R,11R,16S,17S configuration for this compound. Access to the 15 
crystal structure permitted us to validate those NMR data, certifying the relative stereochemistry of the 
stereogenic centre created during the aza-Michael addition and the configuration of the asymmetric 
quaternary carbon 11, previously generated during the TRAL-alkylation. The stereoselectivity of the 
reduction step could be supported by the literature which described the reduction of substrates bearing 
a hydrogen bond donor (HBD) on an asymmetric carbon in the α-position of the carbonyl to reduce.46 20 
The hydride source, supposedly positioned in the same plane than the HBD, could explain the 
produced selectivity during the reduction step, thanks to a dihydrogen bond formation.47 A second 
plausible explanation to the observed total stereoselectivity could also be the steric hindrance at the Si 
face generated by both alkyl groups in α and α’ position of the ketone. Consequently, the attack of the 
hydride would occur by the less hindered Re face, yielding only the 17S diastereoisomer. 25 
  
Benefiting from these results, we decided to turn our attention to the simple version of the TRAL, 
which presents the advantage of a quantitative yield. Thus switching from the TRAL-alkylation to the 
TRAL reaction followed by an appropriate alkylation step, we envisioned to apply the precedent 
synthetic pathway. 30 
 
Second route to spirolactam scaffolds 
 
The activated N,N’-bis-Boc-cyclo-[Gly-(D)-Val] model was here submitted to the TRAL conditions, 
allowing the synthesis of the aminotetramate 5. When O-alkylation conditions, using ethyl 2-35 
(bromomethyl)acrylate, were applied to the TRAL product, a concomitant and opportune Claisen 
rearrangement took place, giving us access to compound 6 in a single step (Scheme 3). 
 
Based on a previous study on O-alkylation of aminotetramates,43 we postulated that the reaction did 
not proceed through a direct C-alkylation. We could notice here that the subsequent Claisen 40 
rearrangement was completed at room temperature without any addition of catalyst, which is unusual 
for such a sigmatropic rearrangement.48 The main advantage of this step lies in its total 
diastereoselectivity, which could be explained by a representation of the Zimmerman-Traxler chain-
like transition state (Scheme 3).48 The isopropyl side chain creates a strong steric hindrance, preventing 
the formation of the R,R isomer. Compound 6 was prepared here with a greatly improved yield of 70% 45 
compared to its diastereoisomeric construct synthesized by the first route. 
 
Following our preliminary study, Boc protecting groups were removed in pure TFA before 
neutralizing the TFA salt,49 to generate compound 7 (Scheme 4). The tandem reaction described for 
the first route, involving a spirocylisation concomitant with an aza-Michael addition and an imine 
formation, was then applied to this pyrrolidine-2,4-dione yielding, after a suitable acidic work-up, 95% 
of a functionalized spirolactam 8. Purification of the mixture of the two diastereoisomers allowed us to 
isolate 8a and 8b with 40% and 45% respective yields.  
   5 
Compound 8a was then submitted to a stereoselective reduction step to yield 10a, unfortunately 
uncrystallisable. Unexpectedly, cautious 2D-NMR experiments performed on compound 10a and 
meticulous comparison with data obtained earlier during the synthesis of product 4, led us to highlight 
a remarkable epimerisation of the asymmetric carbon bearing the isopropyl group.  
 10 
We were intrigued to observe in this second route, and not in the first one using the TRAL-alkylation 
(Scheme 2), a quasi-total inversion of configuration of one stereogenic center (>90% de), instead of a 
more expected partial loss of stereochemistry due to the imine-enamine intermediate equilibrium.   
 
Regarding opposite and equal specific rotations, but also identical 1D NMR spectra, of 10a and 4, it 15 
appeared obvious that we were in the presence of two enantiomers. Careful NOESY experiments 
confirmed those data by highlighting a strong correlation between H17 and H16 and between H17 and 
NH7 while no sign of correlations between H16 with H10 and H10’ were detected. We founded of 
interest to develop arguments to explain this serendipitous epimerisation, which seemed to be related 
to the formation of the undesired imine during the tandem reaction. 20 
 
To understand precisely at which step this epimerisation exactly occurred, we performed similar 
NOESY experiments on the spirolactam 9, prepared by simply heating primary amine 7 in absolute 
ethanol, using microwave irradiation, without any addition of benzylamine. NMR analyses of 
compound 9 revealed this time no correlation between H11 and NH5, confirming the retention of the 25 
configuration of C11 during the heating step. The same epimerisation could be further observed, with 
an identic diastereomeric excess, only when the spirolactam 9 was converted into compound 8 in 
presence of benzylamine under microwave heating. As a first conclusion, the epimerisation seemed to 
be clearly induced by the presence of benzylamine and could find its explanation in the Schiff base 
formation. 30 
 
A proposed mechanism which could explain the high stereoselectivity of this epimerisation process is 
depicted in Scheme 5. We suggested here that in the imine/enamine equilibrium, the C11 could switch 
from sp3 to sp2 allowing us to easily consider a potential epimerisation of the product. To explain the 
observed quasi total inversion, promoting the formation of one epimer in favour of another, we 35 
proposed a pericyclic reaction involving the lactam group borne by cycle A and the enamine group of 
the cycle B. In the representation proposed in the Scheme 5, due to the bottom face localization of the 
lactam, the sp2 carbon C11 seems to have no choice but to catch the NH proton via the same Re face to 
become sp3 again, resulting in the inversion of configuration of C11. This postulated mechanism is 
also coherent with the absence of epimerisation observed initially for spirolactam 4. Following a 40 
similar representation, the lactam would be located, this time, at the top face of cycle A, the pericyclic 
reaction resulting in the retention of the configuration of C11. 
 
En route to the construction of folded edifices 
 45 
Having efficient access to spirolactam building blocks, helpful for the construction of folded edifices, 
we then intended (i) to firstly take advantage of the hydroxyl group generated previously for 
crystallization, thinking that this additional point of functionalization could be useful to decrease the 
keto reactivity but also to further build larger structures, (ii) to secondly remove the benzyl protecting 
group to release a free amino group in order to link the two spirolactams units, (iii) to finally proceed 
to the dimerisation itself. 
 
Reduction of the spirocycles 8a or 8b using sodium borohydride furnished monomers 10a and 10b 
with an excellent yield and a total diastereoselectivity, while an hydrogenolysis of 8a or 8b, using Pd/C 5 
10% under a hydrogen atmosphere in an acidic medium, easily led to the desired primary amines 11a 
and 11b. The linking of the two monomers 10 and 11 was then performed on each diastereoisomer by 
creating an urea bond in presence of triphosgene and DIPEA.50 Dimers 12a and 12b were finally 
isolated with a good yield after purification by preparative HPLC (Scheme 6). 
 10 
To summarize this chemical part of our report, TRAL reaction products were used as spirolactam 
precursors and helped us to highlight an unprecedented total inversion of configuration based on a 
pericyclic reaction. An elegant 6-step pathway was developed, leading us to access to innovative 
constrained dimeric spirocyclic constructs with a good overall yield of 47-49%. 
 15 
To gain information on local secondary structures of our dimers, we then decided to use circular 
dichroism (CD) analytical technic. Obviously, this is the most popular technique to determine spatial 
arrangement of chiral molecules, especially conformations of proteins, peptides and more particularly 
polyproline II secondary structures.24,51  
 20 
CD results of the synthesized spirolactam constructs will be then presented afterward to explore their 
conformational state of the synthesized spirolactam constructs, although our structures were not related 
to peptides and being aware of the fact that CD spectra interpretation can be misleading when dealing 
with non-peptidic structures. 
 25 
Folded potential of compound 12a 
 
CD spectra of monomers and dimers were recorded, analyzed and compared with the CD spectrum of 
the hexapeptide H-(Pro)6-NH2 synthesized in our laboratory. The CD spectrum of H-(Pro)6-NH2 in 
phosphate buffer, as PPII helices, showed a positive -* band around 204 nm and a negative n-* 30 
band around 226 nm. The spectral features were extremely characteristic, easy to differentiate from 
other secondary structures, and typically intensified in the presence of a chaotropic agent such as 
guanidine hydrochloride, which favored the PPII structure (for details refer to Electronic Supporting 
Information).51,30,52,53  
 35 
As expected, CD spectra of all monomers presented data which were not in favour of a PPII folded 
potential but which could be more qualified as unordered forms (for details refer to Electronic 
Supporting Information). However, the behaviour of our artificial dimer 12a in CD analyses was 
exceptionally and remarkably similar to the one observed with the well-known PPII 
hexaproline.51,53,52,30,54,5540 
In phosphate buffer, a negative band followed by a positive one of greater magnitude were observed, 
with an exact bathochromic effect compared to PPII spectra, which could be correlated with the 
presence of a benzyl moiety or a cis-configuration of amide bonds in lactams. 45 
 
To reinforce this first assumption of a similar behaviour in CD between our molecule and a natural 
PPII, extensive CD studies involving the effect of increasing temperature, and more especially the 
concentration effect in presence of chaotropic agent, were performed underlining a bio-inspired PPII 
conformation of dimer 12a. Regarding the literature,29,51,30,52,53 among the helical structures, PPII helix 
is known for decades to be more resistant to an increase of temperature than any other helix. 
Additional temperature-based variation analyses by CD revealed a PPII characteristic temperature 
effect on the CD spectrum of 12a (Figure 1). The conformational change between two forms occurring 
at 50°C, indicated by the presence of an isodichroic point, is reversible since we recorded, at 5°C, after 5 
this experiment, the same spectrum as before the heating. This point clearly indicated that the dimeric 
construct could assume a preferred folded state. Comparable results were obtained when performing 
CD studies in less polar solvent such as TFE. 
 
The most striking observation was nevertheless the typical intensification of 12a molar ellipticity, 10 
similar to the one of the hexaproline, in the presence of increasing concentrations of a chaotropic 
agent, a typical behavior only displayed by PPII helix among natural secondary structures.51,30,52,53 The 
comparable comportment of our dimer and a natural PPII in the presence of chaotropic agent,52 
displayed through a signal reinforcement, which is exceptional with chemical compounds unrelated to 
peptides, are strong arguments in favour of a bio-inspired PPII conformation of 12a. Even though this 15 
dimer copied some of the properties of the PPII helix, we could not affirm that 12a literally mimics a 
PPII helix. 
 
To confirm that CD spectra do not result from the sum of the CD spectra of each building block, the 
same experiments were performed with an equimolar mixture of 10a and 11a corroborating the 20 
importance of the carbamide linker in the PPII-like behaviour of the dimer 12a (for details refer to 
Electronic Supporting Information). 
 
Polyproline II conformation being critical for majority of protein-protein interaction modules, 
molecular modelling analysis was also initiated to illustrate how such a chemical entity could 25 
recognize a SH3 domain. Consequently, compound 12a was docked on the 3D structure of a relevant 
SH3 domain without applying any restraints to the system and using a flexible algorithm to illustrate 
how such conformers could interact and recognize SH3 domains. 
 
Then, a 3D model of a PPII-bound conformation was achieved by a flexible docking of the spiro-30 
compound 12a onto the SH3 domain of the Fyn kinase, a very well described PPII interacting partner 
(PDB code 1EFN).56 The top solutions from the docking simulation were filtered using NMR restraints 
observed in aqueous solution (for details refer to Electronic Supporting Information) and the most 
representative conformation was compared to a pentaproline (Figure 2). The resulting conformation of 
this polyproline demonstrated the potentiality of our heterocyclic framework to mimic the three-35 
dimensionality of PPII helices with a conserved shape, end-to-end distances and 3D-pharmacophoric 
properties (Figure 2). 
 
According to our first results, we have highlighted here efficient access to chemical constructions able 
to fold into artificial structures hypothetically acting as natural polyproline oligomers.40 
Although the correlation between the spirocyclic structures with proline moieties seems unusual, 
molecular modelling studies suggested that the two nitrogens of each spiro groups could be correlated 
to two consecutive nitrogens of a Pro-Pro sequence (Figure 2). The resulting construct could possibly 
be seen as a series of two over-constrained proline bio-inspired structures linked by a flexible arm, 45 
increasing the extended PPII-structural ability of the edifice.  
 
Inspired by biological systems, chemists manage to design and synthesize artificial oligomers able to 
spontaneously fold into well-defined edifices.57 Recently, H.-S. Lee et al. introduced the concept of 
"foldectures" where artificial protein fragments with particular secondary structure self-assembled to 
provide original 3D molecular architectures.58,59 To learn more about the "foldecture" potential of our 
edifice having a specific rigidity and folding predisposition to act as a PPII helix, we undertook 
Scanning Electron Microscopy (SEM) experiments under solvophobic conditions. The SEM images 
revealed 3D shape of an important quantity of diverse rods and sticks, which are ca. 75 µm in length 5 
for the longest with widths of ca. 8.5 µm (Figure 3). 
 
Only a biological evaluation of optimized compounds actually under investigation would permit to 
conclude if 12a indeed behaves as the natural PPII helix does and if specific moieties of the molecule 
are more active than others, such as the carbonyl moieties for example.   10 
 
For this purpose, the affinity of the dimer needs to be improved by adding specific amino acids 
sequences on the compounds side chain to possibly bind specific receptors and hope to be able to 
crystallize the compound in the presence of this biological target such as SH3 domain. 
 15 
Folded potential of compound 12b 
 
Unexpectedly, analysis of CD spectra of dimer 12b, whose structure differs from 12a only by the 
configuration of two stereogenic centres, was incompatible with PPII helix features. The CD spectrum 
displayed a weak negative band around 208 nm and a strong positive band at 227 nm, the signature of 20 
a folded state. One can tentatively compare the shape of the signal with the one of a class B β-turn, 
exhibiting a weak negative band around 187 nm and a strong positive band around 209 nm, a well-
known secondary structure.54 A bathochromic effect compared to class B β-turn spectra could here 
again be correlated with the presence of a benzyl moiety or a cis-configuration of amide bonds in 
lactams. The folding propensity of 12b could be easily disturbed by a chaotropic agent or by increasing 25 
the temperature above 25°C as proven by the loss of its signature, a completely opposite behaviour 
compared to 12a. This particularity was hypothetically consistent with a possible β-turn conformation, 
acknowledged to be stabilized by intramolecular hydrogen bonds. It is important to note that for both 
dimers, the conformational changes induced by the heating were reversible, since we noticed the 
reappearance of the exact same spectrum when cooling back to room temperature. To confirm that CD 30 
spectra do not result from the sum of the CD spectra of each building block, the same experiments 
were performed with an equimolar mixture of 10b and 11b corroborating the importance of the 
carbamide linker in the folding potential of the dimer 12b (for details refer to Electronic Supporting 
Information). 
 35 
While an ever-growing interest on β-turn mimics make this work perhaps less relevant compared with 
neglected PPII mimics, additional studies are actually under investigation to confirm this hypothesis.  
 
Conclusion 
 40 
We described here an efficient access to two dimers capable of adopting a well-defined organization in 
solution, one of these heterocyclic frameworks seeming to behave as polyproline II helix. Its folding 
potential, strongly dependent upon the configuration of its asymmetric carbons, was evaluated using 
CD experiments under various conditions, and molecular modelling based on the nOe constraints 
obtained from advanced NMR analyses. We are confident this work could open a way to the synthesis 45 
of bio-inspired foldamers which could find their use in the comprehension of protein-protein 
interactions but also more generally useful for molecular recognition, catalysis or nanoscience. 
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Figures 20 
 
 
 
 Scheme 1 Proposed mechanism for the TRAL and the TRAL–alkylation. 
 25 
  
Scheme 2 Synthesis of spirolactams using the TRAL–alkylation reaction. 
 
 5 
 
 
 
 
Scheme 3 Diastereoselective O-alkylation–Claisen rearrangement tandem reaction. 10 
  
Scheme 4 Synthesis of spirolactam diastereoisomeric mixture 8. 
 
 5 
 
 
 
Scheme 5 Proposed pathway for the highly stereoselective epimerisation process. 
 10 
  
Scheme 6 Dimerisation of spirolactams 8a and 8b to access 12a and 12b. 
 
 5 
  
Fig. 1 CD experiments in phosphate buffer; A and B: effect of the increasing temperature on the global 
shape of 12a and 12b signals respectively; C and D: effect of increasing concentrations of guanidinium 
chloride on the global shape of 12a and 12b signals, respectively. 5 
 
 
 
 
 10 
  
 Fig. 2 (A) Representation from modelling studies of PPII bio-inspired spirocyclic dimers 12a 
(right) and a pentaproline in PPII conformation (left) (modelled from PDB code 1EFN). (B) 
Representation of the crystallographic structure between Nef polyproline (sticks with atoms colour-5 
coded option) and SH3 from Fyn kinase protein (PDB code 1EFN, Conolly-type surface representation 
with depth-colour coded option). The side chains of the pXXp from Nef (residues XX-XX) have been 
replaced by prolines; (C) docking mode of action of 8a after a fully flexible docking by surflex-
GeomX and compatibility assessment with NMR restraints observed in solution; (D) schematic 
analysis of the relative orientation of the spiro groups (orange) with the N- and C-term Pro–Pro 10 
(yellow). 
 
 
 
 15 
 
Fig. 3 SEM images of the self-assembled structure of dimer 12a. 
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